Early intervention with Kan Jang® to treat upper-respiratory tract infections: A randomized, quadruple-blind study.

Autor:	Narimanyan M; Yerevan State Medical University of Armenia, Koryun 2, RA-0025 Yerevan, Armenia., Jamalyan K; Erebouni Medical Center, 14 Titogradyan Str, RA-0087 Yerevan, Armenia., Balyan A; Yerevan State Medical University of Armenia, Koryun 2, RA-0025 Yerevan, Armenia., Barth A; Partus Kvinnohälsa, Korsgatan 4, SE-411 16 Göteborg, Sweden., Palm S; Panafarma Medical Consult AB, Skottorps Castle, SE-312 96 Laholm, Sweden., Wikman G; SHI Research and Development AB, Kövlingevägen 21, SE-312 50 Vallberga, Sweden., Panossian A; Phytomed AB, Bofinkvägen 1, Våxtorp 31275, Sweden.
Jazyk:	angličtina
Zdroj:	Journal of traditional and complementary medicine [J Tradit Complement Med] 2021 Jun 11; Vol. 11 (6), pp. 552-562. Date of Electronic Publication: 2021 Jun 11 (Print Publication: 2021).
DOI:	10.1016/j.jtcme.2021.06.001
Abstrakt:	Background and Aim: Andrographis paniculata and Eleutherococcus senticosus preparations and their fixed combination, called Kan Jang®, are traditionally used for relieving symptoms of upper-respiratory tract infections (URTIs). This study aimed to assess the efficacy of early intervention with Kan Jang® on the relief and duration of inflammatory symptoms during the acute phase of the disease. Experimental Procedure: A total of 179 patients with URTI symptoms received six Kan Jang® (daily dose of andrographolides: 60 mg) or placebo capsules a day for five consecutive days in this randomized, quadruple-blinded, placebo-controlled, two-parallel-group phase II study. The primary efficacy outcomes were the decrease in the acute-phase duration and the mean URTI symptoms score (sore throat, runny nose, nasal congestion, hoarseness, cough, headache, and fatigue). Results: Early intervention with Kan Jang® significantly increased the recovery rate and reduced the number of sick leave days by >21% (0.64/day) relative to that observed in the placebo group (2.38 vs. 3.02 days, p = 0.0053). Kan Jang® significantly alleviated all URTI symptoms starting from the second day of treatment. A superior anti-inflammatory effect of Kan Jang® to that of placebo was also observed on the white blood cell count (p = 0.007) and erythrocyte sedimentation rate (p = 0.0258). Treatment with Kan Jang® was tolerated well. Conclusion: This study demonstrates that early intervention with Kan Jang® capsules reduces the recovery duration of patients by 21% and significantly relieves the severity of typical URTI symptoms. Competing Interests: Georg Wikman declares a conflict of interest because he is the president of SHI Research and Development AB. Staffan Palm, Panafarma Medical Consult AB, is an independent agreement contractor with the Swedish Herbal Institute. Alexander Panossian is self-employed at the research and development company Phytomed AB. He was the former Head of Research & Development at the Swedish Herbal Institute, Gothenburg, Sweden. He has no shares or financial interest in any pharmaceutical company. The other authors declare no conflicts of interest. The funder had no role in the design of the study; collection, analyses, or interpretation of data; writing of the manuscript, or decision to publish the results. (© 2021 Center for Food and Biomolecules, National Taiwan University. Production and hosting by Elsevier Taiwan LLC.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu